Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in.
Inhibrx Biosciences Inc. (INBX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 1,452,707 | $114,763,853 | +10% | 2.05% |
| 2. | Viking Global Andreas Halvorsen | 1,437,705 | $113,578,695 | -20% | 0.3% |
| 3. | Caligan Partners David Johnson | 323,565 | $25,561,635 | +37% | 2.1% |
| 4. | Millennium Management Israel Englander | 275,917 | $21,797,443 | -8% | 0.01% |
| 5. | Partner Fund Management Christopher Medlock James | 265,517 | $20,975,843 | +11% | 2.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.19 | 18,750 | $266,101.88 | 69,843 | 2024-11-20 | Filing | |
| $14.19 | 18,750 | $266,101.88 | 69,843 | 2024-11-20 | Filing | |
| $14.23 | 34,843 | $495,707.88 | 51,093 | 2024-11-19 | Filing | |
| $14.23 | 34,843 | $495,707.88 | 51,093 | 2024-11-19 | Filing | |
| $15.00 | 6,667 | $100,005.00 | 20,443 | 2024-10-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.25 | 25,042 | $807,604.50 | 102,864 | 2025-10-07 | Filing | |
| $32.25 | 16,315 | $526,158.75 | 67,018 | 2025-10-07 | Filing | |
| $32.25 | 308,643 | $9,953,736.75 | 1,267,823 | 2025-10-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,927 | $465,702 | 0.33% | |
| 2. | 3,800 | $255,474 | 0.02% | |
| 3. | 3,394 | $228,179 | 0.07% | |
| 4. | 326 | $21,917 | 0% | |
| 5. | 302 | $20,303 | 0% |
News See All
12 Best Emerging Technology Stocks to Invest In
On December 24, Kevin Simpson of Capital Wealth Planning joined 'Closing Bell' on CNBC to talk about AI tailwinds and the diverging tech picture.
Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now.
10 Most Profitable New Stocks to Buy Now
Earlier on July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into H2 2025.
Hedge Fund and Insider Trading News: Steve Cohen, Cathie Wood, Caledonia Investments, Vapotherm Inc (VAPO), Inhibrx, Inc. (INBX), and More
The cryptocurrency industry eagerly awaits the next decision from the Securities and Exchange Commission after a U.S. court ruling a week ago regarding Grayscale Investments (GBTC).
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now.
Should You Hold Inhibrx (INBX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
5 Best Stocks Under $20 According to Billionaire Andreas Halvorsen's Viking Global
In this piece, we will take a look at the top five best stocks to buy under $20 according to billionaire Andreas Halvorsen's Viking Global.
5 Stocks in Eashwar Krishnan's Tybourne Capital Management Portfolio
In this article, we will take a look at 5 stocks in Eashwar Krishnan's Tybourne Capital Management portfolio.
Is INBX A Good Stock To Buy Now?
In this article you are going to find out whether hedge funds think Inhibrx, Inc. (NASDAQ:INBX) is a good investment right now.
Hedge Fund Resource Center